Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau 217 (pTau-217), an
Labcorp got permission to offer a new blood test that can detect early signs of brain disease like Alzheimer's. This is a tool doctors can use, and it shows Labcorp is growing its medical testing business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.